Is Egrifta (Tesamorelin) Legal in Pennsylvania?

What Exactly Is Tesamorelin and Why Does Its Legal Status Matter?

Tesamorelin is a synthetic analog of endogenous growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile growth-hormone secretion in a physiologically normal pattern, which separates it mechanistically from direct GH injections. The FDA approved the branded product Egrifta in November 2010, making it the first and still the only FDA-approved drug for reducing excess visceral adipose tissue (VAT) in adults with HIV-associated lipodystrophy. A second, higher-bioavailability formulation, Egrifta SV, received FDA approval in December 2019.

Why Legal Status Is Not Automatic for Peptides

Many peptides circulating in the telehealth market have never passed through the FDA drug-approval process. Tesamorelin is different. Because it holds full FDA approval, the legal pathway for patients in any U.S. State, including Pennsylvania, is straightforward: a licensed prescriber writes a valid prescription, and the patient fills it at a licensed pharmacy. No special state-level carve-outs, no gray-area import rules, and no ambiguity about research-chemical classification apply to Egrifta or Egrifta SV when dispensed as the branded product.

Federal Scheduling Status

Tesamorelin is not listed in any schedule under the Controlled Substances Act. The DEA Orange Book does not include it. That means a clinician does not need a DEA-issued controlled-substance registration to prescribe it, and pharmacies do not need to apply controlled-substance dispensing protocols. Pennsylvania's Controlled Substance, Drug, Device and Cosmetic Act (35 P.S. §§ 780-101 et seq.) similarly does not list tesamorelin, so no state-level scheduling restriction applies.

FDA Approval, Labeling, and the Pennsylvania Prescriber

The Approved Indication

The FDA-approved labeling for Egrifta SV specifies one indication: "treatment of excess abdominal fat in HIV-infected patients with lipodystrophy." The key Phase 3 data supporting this approval came from two randomized, double-blind, placebo-controlled trials (Study 1, N=412; Study 2, N=412) published in the Journal of the American Medical Association. After 26 weeks, tesamorelin 2 mg subcutaneously once daily reduced VAT by a mean of 15.2% versus 5.0% in the placebo group (P<0.0001). [1]

Off-Label Prescribing in Pennsylvania

Pennsylvania clinicians may lawfully prescribe Egrifta for indications beyond HIV lipodystrophy. The Pennsylvania Medical Practice Act (63 P.S. § 422.1) does not prohibit off-label prescribing; it requires only that the prescriber exercise reasonable medical judgment. The FDA itself has stated that off-label use of approved drugs is common, legal, and sometimes the standard of care. Off-label indications for which tesamorelin is being studied include non-alcoholic fatty liver disease (NAFLD) and age-related decline in GH secretion. [2]

A clinician prescribing off-label should document: the clinical rationale, relevant lab values (IGF-1, fasting glucose, HbA1c), informed consent discussion, and a plan for monitoring adverse effects.

Pennsylvania State Pharmacy Law and Dispensing Rules

The Pennsylvania State Board of Pharmacy

The Pennsylvania State Board of Pharmacy licenses all retail and specialty pharmacies operating in the state. Any pharmacy holding a valid Pennsylvania license may dispense Egrifta or Egrifta SV against a lawful prescription. Specialty pharmacies, which are the most common dispensing channel for Egrifta given its cold-chain storage requirements and high cost, must also comply with Pennsylvania's Drug Device and Cosmetic Act. [3]

Mail-Order and Out-of-State Pharmacies

Mail-order pharmacies dispensing to Pennsylvania patients must hold a Pennsylvania nonresident pharmacy permit issued by the State Board of Pharmacy, per 49 Pa. Code § 27.18(p). A large portion of branded Egrifta is dispensed through specialty mail-order pharmacies affiliated with HIV treatment centers or national specialty pharmacy networks. Patients should confirm that any mail-order pharmacy they use carries this permit before initiating therapy.

Compounding of Tesamorelin: The Complicated Part

FDA Bulk Drug Substance Lists and 503A Pharmacies

This is where the legal picture becomes more complicated. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare drug products without FDA approval only if the active pharmaceutical ingredient (API) appears on FDA's approved bulk drug substance list or meets other specific criteria. [4]

The FDA has published a list of bulk drug substances under evaluation for 503A compounding. As of the most recent update, tesamorelin is not on the Category 1 (nominated and appropriate for compounding) list. The FDA's concern is that a compounded version of an FDA-approved drug creates a regulatory conflict: because Egrifta exists as an approved product, compounding that duplicates it is generally prohibited unless a patient has a documented allergy or intolerance to an ingredient in the commercial product that a compounder can address. The FDA's current 503A bulks policy makes this restriction explicit. [5]

503B Outsourcing Facilities

Section 503B outsourcing facilities, which produce larger-volume sterile preparations without patient-specific prescriptions, face the same restriction. The FDA's 503B policy does not include tesamorelin on the clinical need list for outsourcing facilities. [6] A 503B facility dispensing compounded tesamorelin to Pennsylvania patients would be operating outside FDA guidance, which creates legal exposure for both the facility and the prescribing clinician.

What This Means for Pennsylvania Patients

Pennsylvania patients who see advertisements for "compounded tesamorelin" at a lower price point than branded Egrifta should be aware of this regulatory gap. The product may exist, but the pharmacy producing it may be operating in a gray area that exposes patients to unverified purity, potency, and sterility. The branded product, Egrifta SV, is subject to FDA manufacturing standards under 21 CFR Parts 210 and 211. [7]

HealthRX Clinical Framework: Tesamorelin Access Decision Tree for Pennsylvania Patients

1. HIV lipodystrophy diagnosis confirmed by clinician. Prescription for branded Egrifta SV is fully lawful. Proceed to a licensed Pennsylvania or nonresident specialty pharmacy.
2. Off-label indication (NAFLD, age-related GH decline, body composition). Prescription is lawful under Pennsylvania medical practice act. Branded product only; compounded version carries regulatory risk.
3. Patient cannot afford branded product. Clinician should explore Theratechnologies' patient assistance program and confirm whether the compounding rationale (documented allergy/intolerance to excipient) meets the 503A exception before routing to a compounding pharmacy.
4. Patient was quoted "tesamorelin" by a non-pharmacy online vendor with no prescription required. This is not a legal pathway under federal or Pennsylvania law. Do not proceed.

How to Get a Tesamorelin Prescription in Pennsylvania

Step 1: Find a Qualified Prescriber

Any Pennsylvania-licensed physician (MD/DO), certified registered nurse practitioner (CRNP), or physician assistant (PA-C) with prescriptive authority may write a tesamorelin prescription. For the HIV-lipodystrophy indication, infectious disease specialists and HIV primary care physicians are the most common prescribers. For off-label indications, endocrinologists and hormone-specialist physicians see these patients most frequently. [8]

Step 2: Get Baseline Labs

Before initiating tesamorelin, a clinician should order:

• IGF-1 (insulin-like growth factor 1) to establish a baseline and monitor for supraphysiologic elevation
• Fasting glucose and HbA1c, because tesamorelin can cause glucose intolerance [9]
• A lipid panel and waist circumference or DXA-based VAT measurement to quantify the clinical problem

The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults recommends IGF-1 monitoring every 1 to 2 months during the dose-titration period and every 6 months once stable. [10] That framework applies by analogy to tesamorelin, where IGF-1 is also used as the primary safety biomarker.

Step 3: Obtain the Prescription and Choose a Pharmacy

The prescriber sends the prescription to a specialty pharmacy. Egrifta SV is supplied as a 2 mg lyophilized powder requiring reconstitution with sterile water and subcutaneous self-injection. Cold-chain shipping is required; most specialty pharmacies handling this medication ship with ice packs or refrigerated packaging. The manufacturer, Theratechnologies, maintains a specialty pharmacy network and a patient support program; the prescriber's office can contact Theratechnologies directly at 1-833-THE-LINE or visit their patient assistance portal. [11]

Telehealth Prescribing in Pennsylvania

Pennsylvania joined the Interstate Medical Licensure Compact (IMLC) in 2019. A physician licensed in any IMLC member state who has obtained an IMLC Letter of Qualification may prescribe to Pennsylvania patients via telehealth without holding a full Pennsylvania state medical license. This means Pennsylvania residents can legally access tesamorelin through HealthRX or other telehealth platforms staffed by IMLC-credentialed physicians. [12]

Pennsylvania also has its own telehealth statute, Act 2020-133, which codifies that a valid patient-physician relationship can be established via synchronous audio-video encounter. A prescriber cannot rely on an asynchronous questionnaire alone (no audio-video contact) to initiate a controlled substance, but tesamorelin is not a controlled substance, so the bar is lower. Even so, a synchronous clinical encounter is best practice and what most legitimate telehealth platforms require. [13]

Insurance Coverage and Cost in Pennsylvania

Commercial Insurance

Egrifta SV carries a list price that places it among the more expensive specialty drugs on the market. For the FDA-approved HIV lipodystrophy indication, many commercial insurance plans in Pennsylvania cover it under the specialty tier, subject to prior authorization. The prescribing clinician typically needs to submit: the HIV diagnosis (ICD-10: B20), documentation of lipodystrophy (ICD-10: E88.1), and often a DXA or CT scan showing elevated VAT. [14]

Medicare and Medicaid (PA Medicaid / Medical Assistance)

Medicare Part D plans vary in their formulary placement of Egrifta SV. Pennsylvania's Medical Assistance (Medicaid) program may cover it for eligible HIV-positive patients; coverage is subject to Department of Human Services formulary decisions and prior authorization requirements. For the most current formulary status, prescribers should check the Pennsylvania Department of Human Services Drug Formulary.

Patient Assistance

Theratechnologies operates a patient assistance program for uninsured or underinsured patients. Clinicians can initiate the process through the prescriber support line. A 2022 review of specialty drug access programs found that manufacturer-sponsored patient assistance programs reduced out-of-pocket costs to less than $50 per month for eligible patients in the majority of enrolled cases. [15]

Safety Considerations That Inform Legal and Clinical Monitoring Obligations

Clinicians prescribing tesamorelin in Pennsylvania take on obligations under the standard of care. The most clinically relevant adverse effects from the Phase 3 trial data include:

• Glucose intolerance and worsening of pre-existing diabetes. In the JAMA Phase 3 trial, HbA1c increased by 0.12% in the tesamorelin arm versus 0.02% in placebo after 26 weeks. [1] Patients with poorly controlled type 2 diabetes (HbA1c >8%) were excluded from the key trials, and the FDA label carries a warning about this risk. Prescribers should monitor fasting glucose and HbA1c at 3-month intervals.
• Fluid retention and joint pain, consistent with known GH-class effects. Both were reported at rates above 5% in the treatment arm.
• IGF-1 elevation above the age-adjusted normal range in approximately 30% of patients at some point during the trial. The label instructs dose interruption if IGF-1 remains persistently elevated. [16]

The American Diabetes Association's 2024 Standards of Care flag GH-axis drugs as a class requiring glucose monitoring, which supports the monitoring framework above. [17]

Pennsylvania Medical Practice Act: Clinician Liability Considerations

Documenting Off-Label Use

Pennsylvania's Medical Practice Act requires clinicians to maintain adequate medical records. The Pennsylvania State Board of Medicine's regulations at 49 Pa. Code § 16.95 specify that records must reflect the clinical basis for prescribing decisions. For off-label tesamorelin use, this means the chart should include: the patient's presenting complaint and relevant history, objective findings (labs, body composition data), the clinical rationale for choosing tesamorelin over alternatives, a summary of the informed-consent discussion, and a monitoring plan. [18]

Avoiding Prescribing Red Flags

Pennsylvania's Board of Medicine has cited the following patterns in disciplinary actions involving hormone and peptide prescribing: prescribing without a physical or audio-video examination, prescribing to patients the clinician has never evaluated, and failing to monitor for known adverse effects. None of these patterns apply to a legitimate tesamorelin prescription workflow, but clinicians should be aware of them when evaluating any telehealth platform they partner with.

Summary of the Legal Framework in One Table

| Factor | Status in Pennsylvania | |---|---| | FDA approval status | Approved (Egrifta / Egrifta SV) | | Federal scheduling | Not scheduled (non-controlled) | | State scheduling | Not scheduled under 35 P.S. §§ 780-101 | | Prescription required | Yes | | Off-label prescribing | Lawful with documented rationale | | 503A compounding | Restricted; not on FDA Category 1 bulks list | | 503B compounding | Restricted; not on FDA clinical need list | | Telehealth prescribing | Lawful under Act 2020-133 and IMLC | | Insurance coverage | Conditional on prior authorization for approved indication |